Video

Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Author(s):

Loretta J. Nastoupil, MD,Marc S. Hoffmann, MD

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.

Related Videos
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Related Content
Non–Small Cell Lung cancer | Image Credit: © Axel Kock – stock.adobe.com
December 21st 2024

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Image Credit: © Anatomy Insider - stock.adobe.com
December 19th 2024

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 17th 2024

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 16th 2024

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer